Edwin G. Bovill, MD, FAHA, FACP, FASCP, FRCS

Education:

Medical School
University of California San Francisco

Training:

Residency

McGill University
University of Vermont
University of Otago, New Zealand
University of Cambridge, UK

Fellowship

University of California San Francisco
University of Minnesota

Specialty:

Hematopathology/Coagulation

Certifications:

Anatomic and Clinical Pathology
General Surgery

Academic Appointments:

Professor and Chair
Department of Pathology
University of Vermont

Biography:

Dr. Bovill has served as Chair of the Department of the Department of Pathology at the University of Vermont College of Medicine since 1993. He is active in numerous national and international societies related to his research in hemostasis. He is the Director of the Special Coagulation Laboratory at the University of Vermont's academic medical center and is active in the hemostasis clinical laboratory communities nationally and internationally. His present research focuses on the genetic epidemiology of venous thromboembolic disease and clinical trials of novel anticoagulant drugs under development. He is an active co-investigator in our NHLBI Hemostasis Training Grant (PI-K Mann, Department of Biochemistry).

Major Research Interests:

Participated as an investigator in numerous large clinical trials with respect to hemostatic mechanistic studies including: TAMI, TIMI, GUSTO, Cardiovascular Health Study, SPAF and Xanadu. Developed techniques to elucidate gamma glutamic carboxylation in warfarin therapy, including assessment of vitamin K metabolism. Studied the vitamin K dependent hemostatic development across the spectrum of premature to term neonates. The major focus of Dr. Bovill's present efforts are on gene discovery in venous thromboembolic disease. He is presently studying a large (n=900) French Canadian kindred with protein C deficiency and clinical juvenile thrombophilia. Genetic epidemiological studies have demonstrated that there is a second major locus (Lod score = 6.0) interacting with protein C to cause thrombosis which is not one of the usual suspects (eg Factor V Leiden, prothrombin G20210A polymorphism etc). An 8 centi-Morgan gene scan has been completed, and his group is actively pursuing a number of promising loci for genes linked to thrombosis as well as selected hemostatic risk factors treated as quantitative traits. This study is being performed by the International Protein C Investigators (IPCI), reflecting close collaboration of the Vermont investigators with NHLBI co-funded groups at the University of Paris, University of Laval (Quebec), University of Leiden and the University of Utah. Of interest, Dr. Bovill's group has recently traced the identical abnormal protein C allele to a couple who introduced the allele to Quebec in the year 1669.

Recent Grant Support

Grant title: Stroke Prevention in Atrial Fibrillation (SPAF)
Sponsor: NINDS
Co investigator: E Bovill, R Hart University of Texas PI

Grant tile: Hemostasis Training Grant, University of Vermont College of Medicine
Sponsor: NHLBI
Co investigator: E Bovill, K Mann PI Department of Biochemistry University of Vermont College of Medicine

Grant title: Gene Discovery and Risk Assessment in Venous Thromboembolic Disease
Sponsor: NHLBI
PI: E Bovill, (project within program project, K Mann PI)

Grant title: Phase I, II and III clinical trials entitles "Xa neutralization for Atherosclerotic Disease"
Sponsor: Subcontract with Duke University Cardiovascular Research Center for Mechanistic hemostatic studies.
PI: E Bovill

Grant title: Marshfield Clinic Genome Scan (Core Labratory funded to perform genome scans, used for our thrombophilia study).
Sponsor: NHLBI
PI: E Bovill

Publications:

Representative Publications from a Total of 199

Lawler CM, Bovill EG, Stump DC, Collen DJ, Mann KG, Tracy RP: Fibrin fragment D-dimer and fibrinogen B? peptides in plasma as markers of clot lysis during thrombolytic therapy in acute myocardial infarction. Blood 76:1341-1348, 1990.

Bovill EG, Tomczak JA, Grant B, Bhushan F, Pillemer E, Rainville IR, Long GL: Protein CVermont: Symptomatic type II protein C deficiency associated with two GLA domain mutations. Blood 79:1456-1465, 1992.

Bovill EG, Soll RF, Lynch M, Bhushan F, Landesman M, Freije M, Church W, McAuliffe T, Davidson K, Sadowski J: Vitamin K1 metabolism and the production of des-carboxy prothrombin and protein C in the term and premature neonate. Blood 81:77-83, 1993

Lu D, Bovill EG, Long GL: Molecular mechanism for familial protein C deficiency and thrombosis in Protein C Vermont (Glu20 ?Ala, Val34? Met). J Biol Chem 269:29032-29038, 1994.

Bovill EG, Tracy RP, Hayes T, Jenny RJ, Bhushan FH, Mann KG: Evidence that meizothrombin is an intermediate product in the clotting of whole blood. Arterioscler Thromb Vasc Biol 15:754-758, 1995.

Couture P, Bovill EG, Demers C, Simard J, Delage R, Scott BT, Valliere JE, Callas PW, Jomphe M, Rosendaal FR, Aiach M, Long GL: Evidence of a founder effect for the protein C gene 3363 inserted C mutation in thrombophilic pedigrees of French origin. Thromb Haemost 86:1000-1006, 2001.

Vossen CY, Hasstedt S, Rosendaal FR, Callas PW, Bauer K, Broze GJ, Hoogendorn H, Long G, Bovill EG: Heritability of plasma concentrations of clotting factors and measures of prethrombotic state in a protein C deficient family. J Thromb Haemost 2:242-247, 2004.

Vossen CY, Hasstedt SJ, Scott BT, Rosendaal FR, Bovill EG: A genome search for genetic determinants of markers of protein C activation. J Thromb Haemost 4:706-708, 2006.

Svensson AM, Whiteley GR, Callas PW, Bovill EG: SELDI-TOF plasma profiles distinguish individuals in a protein C-deficient family with thrombotic episodes occurring before age 40. Thromb Haemost 96:725-730, 2006.

Vossen CY, Hasstedt SJ, Demers C, Rosendaal FR, Bovill EG: Linkage analysis for 3 coagulation factors clustering on chromosome 13q34: factor VII, factor X and protein Z. J Thromb Haemost March 31, 2007 [Epub ahead of print].